Last reviewed · How we verify

Xofigo — Competitive Intelligence Brief

Xofigo (RADIUM RA 223 DICHLORIDE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: radium Ra 223 dichloride. Area: Oncology.

marketed radium Ra 223 dichloride Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Xofigo (RADIUM RA 223 DICHLORIDE) — Bayer. Xofigo works by emitting alpha particles that selectively target and kill cancer cells in the prostate.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xofigo TARGET RADIUM RA 223 DICHLORIDE Bayer marketed radium Ra 223 dichloride 2013-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (radium Ra 223 dichloride class)

  1. Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xofigo — Competitive Intelligence Brief. https://druglandscape.com/ci/radium-ra-223-dichloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: